Infliximab (Remicade): the magic bullet for Crohn's disease?
D'Haens
G
G
Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium. geert.dhaens@imelda.be
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab